Red, thanks for the list. What you posted are definitely important but not the type of deals I am talking about. Those are not revenue generating deals. Those are deals where AMBS has had to pay for the rights of various technologies or support. The ICON deal could eventually blossom into something significant. What I am referring to is where another BP partners with AMBS because it wants what AMBS has and will pay for it with up front money and future revenue distribution. We haven't seen that yet. Hopefully we will see something soon or at least see Lympro burst out of the gate with BPs clamoring to use it for their clinical trials.